Based on crucial molecular markers, including estrogen and progestin receptors and human epidermal growth factor receptor 2 (HER2), the disease entity is classified into major subtypes: hormone receptor (HR) positive, HER2-positive, and triple-negative breast cancers (TNBC). This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.